SII CEO POONAWALLA THANKS US PRESIDENT BIDEN, INDIAN EAM JAISHANKAR FOR POLICY CHANGE ON VACCINE

Highlights

• In a response to Poonawalla’s tweet, the India’s EAM said that the “Indian diplomacy is focussed on securing the vaccine supply chain.”

Responding to the decision made by the United States to remove Defense Production Act priority rati...

COVISHIELD VACCINE MAYBE RECOMMENDED FOR INTERNATIONAL USE

HIGHLIGHTS

• AstraZeneca is in talks with governments of many countries.
• AstraZeneca is also engaging with multilateral organizations and many other partners around the world.
• AstraZeneca wants broad and equitable access to the vaccine for ev...

SII RELEASES FAQ FACTSHEET FOR COVISHIELD VACCINE

HIGHLIGHTS

• SII has released FAQ Factsheet for Covishield Vaccine.
• The new factsheet details information for vaccine recipients regarding the benefits and common side-effects of the Covishield vaccine.
• The Covishield has been approved for re...

COVID-19 VACCINE: NOVAVAX TO DELIVER 100 MILLION DOSES TO THE U.S. BY JANUARY 2021

Highlights

• Novavax in the month of August had inked a deal with Serum Institute of India, the largest producer of vaccines in the world in order to produce a minimum of its COVID-19 vaccine candidate

• The U.S. drug developer had previously said that it will supply...

SERUM INSTITUTE CEO WARNS OF COVID-19 VACCINE SHORTAGE TILL 2024

HIGHLIGHTS

• Serum Institute CEO says that till 2024, coronavirus vaccine availability will not be enough.
• Two doses of vaccine are required to create immunity against coronavirus.

On Monday, 14 SEP 2020, Adar Poonawalla, the CEO of Se...

COVID-19 VACCINE: SERUM INSTITUTE OF INDIA TO COMMENCE PHASE II TRIAL OF OXFORD VACCINE TODAY

According to the sources, the phase II human clinical trial of the Oxford COVID-19 vaccine candidate by the Serum Institute of India (SII), Pune will start from today. Bharati Vidyapeeth Medical College and Hospital in Pune is the site where this observer-blind, randomised controlled study to det...

COVID-19 VACCINE: SERUM INSTITUTE OF INDIA TO BEGIN PHASE 2 TRIALS OF OXFORD VACCINE THIS WEEK

Highlights

• The Serum Institute of India has stated that it has shortlisted 10 centres across the nation to conduct Phase II and Phase III human clinical trials of COVID-19 vaccine developed by the University of Oxford

• On Monday, the national expert group on vacci...

INDIA’S COVID-19 TALLY AT 27,02,742, DEATH TOLL GOES UP TO 51,797

• Current Total Cases: 2,702,742

• Total Deaths : 51,797

• Cumulative recoveries : 1,977,779

• Active cases: 673,166

• Top five states that has the maximum number of cases : 

Maharashtra: Cases 604,358, number of deat...

COVID-19 VACCINE: SERUM INSTITUTE OF INDIA CAPS PROPOSED VACCINE AT $3/DOSE

Highlights

• The Serum Institute of India, Pune has signed an agreement with Gavi and Bill & Melinda Gates Foundation to accelerate the development and distribution of up to 100 million doses

• As per the agreement signed by the Serum Institute with AstraZeneca a...

NOVAVAX, SERUM INSTITUTE OF INDIA JOIN HANDS TO SUPPLY COVID-19 VACCINE

Highlights

• The Serum Institute of India will have exclusive rights for the COVID-19 vaccine in India and non-exclusive rights during the pandemic period in all countries except those designated as upper-middle or high-income nations

• The COVID-19 vaccine developed...

COVID-19 VACCINE: DCGI APPROVES PHASE 2 AND 3 CLINICAL TRIALS OF OXFORD VACCINE BY SERUM INSTITUTE

Highlights

• DCGI Dr V G Somani granted approval for conducting phase 2 and 3 human clinical trials by the SII

• ‘Covishield’ a potential vaccine for COVID-19 has been developed by the University of Oxford

• Before starting the phase 3 tria...

PUNE-BASED MYLAB GETS COMMERCIAL APPROVAL FROM ICMR FOR ANTIGEN KITS

Highlights

• The antigen kit developed by Mylab Discovery Solutions will cost Rs 450 per unit

• Serum Institute of India, CEO Adar Poonawalla has invested over Rs 100 crore and owns less than 50 percent stake in Mylab

• This antigen kit was co-develope...